Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole extended-release versus esomeprazole for moderate to severe erosive GERD
2007-006046-17Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) comparing Rabeprazole extended-release 50 mg with Esomeprazole 40 mg (2 arms). Primary endpoint: Endoscopic healing at 4 weeks. Started May 2008; status: completed.
02
Drugs
rabeprazoleesomeprazole
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2007-006046-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006046-17.